.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,331,398

« Back to Dashboard

Details for Patent: 6,331,398

Title: Nucleic acid ligands
Abstract:This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.
Inventor(s): Gold; Larry (Boulder, CO), Tuerk; Craig (Morehead, KY)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Feb 10, 2000
Application Number:09/502,344
Claims:1. A method of identifying a function-modifying nucleic acid ligand that modifies a function of a target molecule comprising:

(a) identifying a nucleic acid ligand to the target molecule;

(b) contacting said identified nucleic acid ligand with the target molecule; and

(c) evaluating whether said identified nucleic acid ligand modifies a function of the target molecule, whereby said function-modifying nucleic acid ligand may be identified.

2. The method of claim 1 wherein said nucleic acid ligand is identified from a candidate mixture of nucleic acids by a method comprising:

(a) contacting the candidate mixture with said target molecule, wherein nucleic acids having an increased affinity to said target molecule relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

(b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

(c) amplifying the increased affinity nucleic acid to yield a ligand-enriched mixture of nucleic acids, whereby said nucleic acid ligand may be identified.

3. The method of claim 1 wherein the target molecule is selected from the group consisting of a protein, a nucleoside, a nucleotide and a coenzyme nucleotide.

4. A function-modifying nucleic acid ligand that modifies a function of a target molecule identified by the method of claim 1.

5. A method of modifying a function of a target molecule comprising:

contacting the target molecule with the function-modifying nucleic acid ligand identified by the method of claim 2 whereby the function of the target molecule is modified.

6. The method of claim 5 wherein the function of the target molecule is a biological function and wherein said method further comprises inhibiting the biological function of the target molecule.

7. The method of claim 6 wherein the biological function of the target molecule is catalysis.

8. The method of claim 7 wherein the function-modifying nucleic acid ligand comprises a nucleic acid ligand to a transition state analogue.

9. The method of claim 7 wherein the function-modifying nucleic acid ligand binds irreversibly to the target molecule.

10. The method of claim 7 wherein the function-modifying nucleic acid ligand comprises a nucleic acid ligand that modifies substrate binding of the target molecule.

11. The method of claim 5 wherein the function of the target molecule is binding a receptor and wherein said function-modifying nucleic acid ligand comprises a nucleic acid ligand that inhibits binding of the target molecule to the receptor or modifies the specificity of binding of the target molecule to the receptor.

12. The method of claim 5 wherein the target molecule is a protein and said method comprises affecting formation of the protein quaternary structure from the protein subunits.

13. The method of claim 12 wherein said affecting formation comprises disrupting quaternary structure of protein subunits.

14. The method of claim 5 wherein said method further comprises modifying transport properties of a protein.

15. The method of claim 14 wherein modifying the transport properties comprises disrupting transport of small molecules or ions.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc